HBOT in Cancer Recovery: Where It May Fit
Hyperbaric oxygen therapy does not treat or cure cancer. In selected patients, it may be considered for specific complications of cancer treatment — particularly some delayed radiation tissue injuries — or for selected wound and reconstruction problems after appropriate oncology and surgical assessment.
People affected by cancer are among the most targeted by unproven treatments, and hyperbaric oxygen is regularly misrepresented in that market. This page states the narrow, genuine role and is equally clear about what is not supported.
HBOT is an adjunct, not cancer treatment
HBOT increases the amount of oxygen carried in plasma while a patient breathes high-concentration oxygen under increased pressure. Its role is indication-specific. It should not be presented as a way to kill cancer cells, prevent recurrence, replace chemotherapy, radiotherapy, immunotherapy, surgery or targeted therapy, or broadly “rebuild the body” after cancer.
Before HBOT is considered, the clinical question should be clear: what complication is being treated, what evidence supports HBOT for that complication, and has the oncology or surgical team been involved where needed?
One claim circulating online deserves direct correction. The idea that cancer “cannot survive in oxygen” and that hyperbaric oxygen therefore kills tumours is a misreading of tumour biology. Tumours do often contain poorly oxygenated regions, and that hypoxia is relevant to how they respond to some treatments — but it does not follow that raising oxygen levels destroys cancer. Anyone offering HBOT as a cancer treatment on that basis is misrepresenting the science.
The one question worth asking
Ask any provider proposing HBOT after cancer: what specific complication are we treating, and what evidence supports hyperbaric oxygen for that complication?
A clear answer names a recognised indication — a particular radiation injury syndrome, a specific compromised graft. A vague answer about recovery, oxygenation, healing or wellbeing is not an indication, and it is the point at which to be cautious.
Situations where HBOT may be discussed
Delayed radiation tissue injury
HBOT has an established role in selected radiation-related soft-tissue or bone injury, depending on the site, severity, timing and specialist assessment.
Complex wound problems
After cancer surgery or reconstruction, some wounds may require multidisciplinary management. HBOT is considered only when the wound indication and patient factors support it.
Selected reconstruction contexts
Compromised grafts or flaps may sometimes be assessed for adjunctive HBOT. It is not routine treatment for every postoperative wound.
| Reason people ask about HBOT after cancer | Is it a recognised indication? |
|---|---|
| Delayed radiation injury to soft tissue or bone | Yes — the strongest cancer-related indication, in selected cases after specialist assessment. |
| Radiation-related bladder or bowel injury | Recognised in selected cases; needs specialist involvement. |
| Compromised graft or flap after reconstruction | May be considered in specific situations, not routinely. |
| Non-healing wound after cancer surgery | Possibly, as an adjunct once circulation, infection and pressure are addressed. |
| Fatigue after chemotherapy | No. Needs assessment for anaemia, thyroid, mood, sleep and other causes. |
| Chemotherapy-related neuropathy | No established role. Neuropathy has its own management pathway. |
| “Chemo brain” or cognitive change | Not supported. Deserves proper assessment rather than a chamber. |
| Lymphoedema | Not supported. Specialist lymphoedema management is the appropriate route. |
| Preventing recurrence or boosting immunity | No. This is not a supported use and should be treated as a warning sign. |
What HBOT should not be promised to improve
Evidence does not support presenting HBOT as a universal treatment for cancer-related fatigue, “chemo brain”, neuropathy, lymphoedema, muscle weakness, sleep problems, chronic pain or emotional stress. Some patients may report symptom changes, but those concerns have many possible causes and should be assessed directly rather than attributed to low tissue oxygen.
For persistent fatigue, weakness, neuropathy, cognitive change or sleep disturbance, appropriate evaluation may involve oncology, rehabilitation, neurology, pain, sleep or primary-care assessment.
None of this dismisses the symptoms. Fatigue and cognitive change after cancer treatment are real, common and often under-addressed. The argument here is that they deserve proper assessment and targeted management rather than an expensive intervention with no established role for them — which is a different thing from being told they are imagined.
Radiation injury is different from routine recovery
Radiation can cause delayed injury to blood vessels, soft tissue or bone months or years after treatment. In selected recognised radiation injury syndromes, HBOT may be used as part of a broader treatment plan to improve tissue oxygenation and support healing.
The benefit varies by indication and should not be generalized to every patient who has previously received radiotherapy.
How Aquila assesses suitability
1. Define the indication
We clarify the cancer history, treatment received, current complication and the clinical goal for HBOT.
2. Review medical risk
Ear and sinus health, lung history, seizure risk, medications, glucose control and other contraindications are reviewed.
3. Coordinate care
Where the patient is under active oncology, radiation oncology or surgical care, coordination is encouraged before starting treatment.
4. Set realistic endpoints
Treatment should have a defined indication and measurable clinical goals rather than an open-ended “wellness” course.
5. Review response
Progress is reassessed and the plan is changed if the expected clinical benefit is not occurring.
6. Continue standard care
HBOT does not replace oncology follow-up, surveillance, wound care, rehabilitation or other indicated treatment.
Coordination is not a courtesy. Your oncology team holds information that changes whether hyperbaric treatment is appropriate — which agents you received, your pulmonary status, the current treatment plan and what is being monitored. A provider willing to start a course without any contact with that team is not managing the risk properly.
HBOT risks and precautions
- Ear or sinus barotrauma and difficulty equalising pressure.
- Temporary visual changes such as myopic shift with repeated exposure.
- Blood-glucose changes in people with diabetes.
- Claustrophobia or anxiety in the chamber.
- Rare oxygen-related seizures or pulmonary oxygen toxicity.
- Fire-safety requirements because oxygen-rich environments increase combustion risk.
- Fatigue during a course, which can be significant alongside cancer-related tiredness.
A course of hyperbaric treatment is also a substantial time commitment, frequently daily over several weeks. For someone already managing appointments and fatigue, that burden is worth weighing honestly against the expected benefit.
When another service may be more appropriate
If the main issue is an open wound, infection concern, dressings or postoperative wound review, start with our Wound Care service. For a broad explanation of HBOT indications, chamber procedures, risks and contraindications, see the main HBOT page.
For wound-specific hyperbaric questions, our HBOT for wound recovery page covers that indication in more detail.
Frequently asked questions
Does HBOT treat cancer?
No. HBOT is not a cancer treatment and should not replace evidence-based oncology care.
Can HBOT be used after radiotherapy?
Sometimes. Its strongest cancer-related role is in selected delayed radiation tissue injuries. Suitability depends on the tissue involved, symptoms, prior treatment and specialist assessment.
Can I have HBOT while receiving active cancer treatment?
That requires individual review. Treatment timing, medication and the oncology plan should be considered with your treating team.
Will HBOT fix fatigue, neuropathy or brain fog after chemotherapy?
HBOT should not be promised as a general treatment for these symptoms. They warrant clinical assessment because management depends on the underlying cause.
How many HBOT sessions are needed?
There is no single cancer-recovery protocol. Session number and pressure should be based on a recognised or clearly defined indication, response and medical supervision.
I read that cancer cannot survive in oxygen — is that true?
No. Tumours often contain poorly oxygenated regions, which matters for how they respond to some treatments, but it does not follow that raising oxygen destroys cancer. Anyone offering HBOT as cancer treatment on that basis is misrepresenting the science.
What should I ask a provider offering HBOT after cancer?
What specific complication is being treated and what evidence supports hyperbaric oxygen for it. A vague answer about recovery, oxygenation or wellbeing is not an indication.
Does it matter which chemotherapy I had?
Yes. Bleomycin in particular has pulmonary considerations recognised in hyperbaric medicine, so your full treatment history must form part of the assessment.
Can HBOT prevent my cancer coming back?
No. That is not a supported use, and a provider suggesting it should be treated with considerable caution.
Why does my oncology team need to be involved?
Because they hold information that changes suitability — agents received, pulmonary status, current plan and what is being monitored. Starting without any contact is not managing the risk properly.
How long after radiotherapy can injury appear?
Months or years, which is why the connection is often missed. Mention your radiotherapy history explicitly if problems arise in a previously treated area.
Are my fatigue and brain fog imagined then?
Not at all. They are real, common and often under-addressed. The point is that they deserve targeted assessment and management rather than an intervention with no established role for them.
What is the time commitment?
A course is frequently daily over several weeks, which is substantial for someone already managing appointments and fatigue. That burden deserves honest weighing.
Can HBOT help lymphoedema?
It is not a supported indication. Specialist lymphoedema management is the appropriate route.
Is it safe if I have lung disease?
It requires careful assessment. Lung history is among the more important safety considerations in hyperbaric medicine.
Will it affect my blood sugar?
It can in people with diabetes, so glucose should be monitored around sessions as part of the treatment plan.
What if I am claustrophobic?
Say so beforehand. Anxiety in the chamber is common and can sometimes be managed, but it should be discussed rather than discovered on the first session.
Does HBOT replace my oncology follow-up?
No. Surveillance, follow-up and any indicated treatment continue under your oncology team regardless.
Is HBOT claimable under MediSave or insurance in Singapore?
Coverage depends on the indication and policy, and recognised medical indications may be treated differently from wellness use. Check directly with your insurer.
Where is Aquila Medical Center?
Aquila Medical Center is at 160 Robinson Road, #05-01 SBF Centre Medical Suites, Singapore 068914, in the CBD, a short walk from Tanjong Pagar, Shenton Way and Telok Ayer MRT stations.
Selected references
- Hyperbaric Oxygen Therapy. StatPearls, NCBI Bookshelf.
- Radiation Therapy Induced Tissue Injury. StatPearls, NCBI Bookshelf.
- US National Cancer Institute. Complementary and alternative medicine in cancer care.
- US Food and Drug Administration. Hyperbaric oxygen therapy: get the facts.
This page is educational and does not replace oncology care. Hyperbaric oxygen therapy is not a cancer treatment. Its cancer-related role is limited to selected recognised complications, principally delayed radiation tissue injury, and requires assessment and coordination with the treating team. Content reviewed by the medical team at Aquila Medical Center, Singapore. Last reviewed: 26 August 2026.
Start with the clinical indication
If you have a radiation-related tissue problem, complex postoperative wound or reconstruction concern, we can assess whether HBOT is a reasonable adjunct and coordinate with your treating team.
If there is no recognised indication, we will tell you that rather than sell a course of sessions.
General information only. Cancer treatment and surveillance remain under the direction of the appropriate oncology team.